Nov 15, 2021 / 04:45PM GMT
Huidong Wang - Barclays Bank PLC, Research Division - Research Analyst
Thank you, everyone, for attending Barclays' first Gene Editing & Gene Therapy Summit. My name is Gena Wang. I'm SMID cap biotech analyst at Barclays. Before I start, I wanted to thank our health care corporate access team and event team to make this event possible. I also want to thank my wonderful team members, Sheldon Fan, [Tong Liu] and [Hashida Apolocheti] who burned the midnight oil to make this summit happen.
Gene therapy and gene editing are still -- is the emerging field among all the therapeutics. And we have seen -- overseeing evolving dynamics from initial skepticism to enthusiasm and now more mature process from the regulator following the initial learning phase.
We will discuss some of the topics in our panel discussion today. In 2021, we saw some progress regarding clinical data and a regulatory update. We finalized our clinical hold removal for spinal muscular atrophy of Zolgensma intrathecal program. We also saw initial impressive data from in vivo genetic approach. We continue to believe
Cellectis SA at Barclays Gene Editing & Gene Therapy Summit (Virtual) Transcript
Feb 06, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers